Relay Therapeutics has delivered a very large 1 year return, yet the stock currently screens as expensive on broad valuation checks, which raises questions about how much optimism is already in the price.

• Relay Therapeutics has returned roughly 7x over the past 12 months, which puts unusual weight on whether the fundamentals can justify that kind of move.
• Expectations for future drug development and potential revenue can support the current valuation, while uncertainty around clinical progress and funding needs may limit how much investors are willing to pay ahead of clearer cash flow.
• The company passes only 1 of 6 valuation checks, so on the broader measures Relay Therapeutics does not look like an obvious bargain.

The issue now is whether Relay Therapeutics' recent share price strength leaves enough valuation support for new investors coming in at current levels.

Has Relay Therapeutics Run Too Far on Book Value?

The P/B multiple is often a useful cross check for a company like Relay Therapeutics that is still loss making and does not have a meaningful earnings base. Relay Therapeutics trades at a P/B of about 5.1x, which is above both the broader Biotechs industry average of 2.5x and the peer group average of around 4.6x.

This indicates that investors are paying a higher price for each dollar of the company’s net assets than for many similar biotechs. That kind of premium can reflect confidence in Relay Therapeutics' research platform or pipeline, but it also leaves less room if sentiment weakens or asset values change. On this simple balance sheet based yardstick, the stock appears more expensive than a typical biotech peer.

Relay Therapeutics appears overvalued on the P/B multiple compared with both its industry and peer averages.

The Relay Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Relay Therapeutics pick up where the valuation checks leave off by spelling out which paths for growth, margins and future earnings would need to play out for the stock to be worth materially more or less than it is today. Rather than giving a single figure for worth, they describe the future that figure relies on so you can watch how Relay Therapeutics' actual progress lines up. These Narratives sit on Simply Wall St's Community page.

You can add your voice to the Simply Wall St community by setting out a clear, number driven narrative on Relay Therapeutics and a view on where its growth, margins and execution go from here. Share your thesis now and see how it holds up as Relay Therapeutics' story develops.

Do you think there's more to the story for Relay Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

Relay Therapeutics screens as overvalued on broad market multiples, with only a small part of the usual valuation checklist supporting the current price. That does not rule out further upside, but it does mean a lot already depends on how the pipeline and execution play out. For new money, the key question is whether Relay Therapeutics can deliver clinical and commercial progress strong enough to keep investors comfortable paying a premium for a business that is still building toward meaningful cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.